INDIANAPOLIS, Jan. 12 /PRNewswire-FirstCall/ -- Eli Lilly and Company today filed a Form 8-K/A with the U.S. Securities and Exchange Commission (SEC) detailing the pro forma impact of the company’s recently- completed acquisition of ImClone Systems. The Form 8-K/A is available on the SEC’s website at www.sec.gov and the investor relations section of the company’s website at www.investor.lilly.com.
The content of the Form 8-K/A includes unaudited pro forma condensed combined financial statements of Lilly and ImClone for the year ended December 31, 2007 and as of and for the nine months ended September 30, 2008. The financial statements were prepared in accordance with accounting principles generally accepted in the United States (GAAP).
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world’s most urgent medical needs. Additional information about Lilly is available at www.lilly.com. F-LLY
(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )
CONTACT: Mark E. Taylor of Eli Lilly and Company, +1-317-276-5795
